Drug Database
Back to search

Netherlands· NL-1e174545086e

ANKTIVA 400 microgram concentraat voor intravesicale suspensie

A medicinal product containing nogapendekin alfa inbakicept, registered in Netherlands by ImmunityBio Ireland Limited.

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedANKTIVA 400 microgram concentraat voo…ATC—REGISTER NO.NL-1e174545086ePACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about nogapendekin alfa inbakiceptAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

The record

At a glance

CBG-MEB (Netherlands)
Active substance
NOGAPENDEKIN ALFA INBAKICEPT
Manufacturer
ImmunityBio Ireland Limited
Country
Netherlands (NL)
ATC code
—
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/25/2002

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Nogapendekin alfa inbakicept in 7 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All nogapendekin alfa inbakicept products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Anktiva
  • Liechtenstein · Anktiva
  • Norway · Anktiva

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/0010351c-1f90-4828-829c-03569d37147a
GET /v1/drugs/0010351c-1f90-4828-829c-03569d37147a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Concentraat voor intravesicale suspensie",
  "route": "Intravesicaal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/anktiva-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": null,
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp134545",
  "excipients": [
    "DINATRIUMWATERSTOFFOSFAAT 0-WATER (E 339)",
    "KALIUMDIWATERSTOFFOSFAAT 0-WATER (E 340)",
    "NATRIUMCHLORIDE",
    "NATRIUMHYDROXIDE (E 524)",
    "WATER VOOR INJECTIE",
    "ZOUTZUUR (E 507)"
  ],
  "substances": [
    "NOGAPENDEKIN ALFA INBAKICEPT"
  ],
  "leaflet_url": null,
  "authorised_at": "2026/02/16",
  "procedure_number": "EMEA/H/C/006622",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/25/2002",
  "additional_monitoring": "Y"
}
API referenceMCP serverPlans

See everything about nogapendekin alfa inbakicept.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console